BBVA USA’s Labcorp LH Stock Holding History

BBVA USA’s Portfolio LH Stock Details LH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$2M	Sell	8,275 -243	-3%	-$61.2K	0.12%	174
2021 Q2	$2.02M	Buy	+8,518	New	+$1.94M	0.11%	180

Other funds holding LH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MCM

Melvin Capital Management New York $9.86B AUM 16.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBVA USA's LH Position: Q3 2021 in Review

BBVA USA reduced its Labcorp (LH) stake by 2.9% in Q3 2021, selling an estimated $61.2K and leaving 8,275 shares worth $2M. The position accounts for 0.12% of the portfolio, ranked #174.

BBVA USA first reported a position in LH in Q2 2021 and has held it in 2 quarters since. The position peaked at $2.02M in Q2 2021. 992 funds tracked by Wall St. Rank hold LH as of Q3 2021.

BBVA USA held 8,275 shares of Labcorp worth $2M as of Q3 2021.
BBVA USA sold 243 Labcorp shares in Q3 2021, an estimated $61.2K.
Labcorp made up 0.12% of BBVA USA's portfolio in Q3 2021, its #174 holding.
BBVA USA first reported a position in Labcorp in Q2 2021 and has held it in 2 quarters since.
BBVA USA's Labcorp position peaked at $2.02M in Q2 2021.
992 funds tracked by Wall St. Rank held Labcorp as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.